← back to search

Zhonghua Wang

Shenyang Pharmaceutical University · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, and Cancer Treatment and Pharmacology.
h-index
29
citations
2,263
works
129
NIH funding
primary concept
email

Recent publications

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
JAMA 2024cited by 40position: middledoi
Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.
Journal of Clinical Oncology 2023cited by 2position: middledoi
CACA Guidelines for Holistic Integrative Management of Breast Cancer
Holistic Integrative Oncology 2022cited by 57position: middledoi
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
Journal of Experimental & Clinical Cancer Research 2021cited by 89position: lastdoi
Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement
Frontiers in Oncology 2021cited by 47position: middledoi
The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
Scientific Reports 2020cited by 185position: lastdoi
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
Nature Communications 2020cited by 84position: middledoi
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)
Cancer 2020cited by 36position: middledoi
miRNA-21 Expression in the Serum of Elderly Patients with Acute Myocardial Infarction
Medical Science Monitor 2017cited by 29position: firstdoi
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
International Journal of Cancer 2014cited by 73position: middledoi
Impact of emergency percutaneous coronary intervention on outcomes of ST-segment elevation myocardial infarction patients complicated by out-of-hospital cardiac arrest.
PubMed 2012cited by 12position: last

Grants

No grants ingested yet.

Frequent collaborators

Zhimin Shao · Shanghai Medical College of Fudan University3 papers (2014–2023)Jiong Wu · Shanghai Medical College of Fudan University3 papers (2014–2023)Guang‐Yu Liu · Shanghai Medical College of Fudan University3 papers (2014–2023)Lanfeng Wang · Harbin Medical University2 papers (2012–2017)Min He · Zhejiang Chinese Medical University2 papers (2021–2023)Gen‐Hong Di · Fudan University2 papers (2014–2020)Binhao Huang · Shanghai Medical College of Fudan University2 papers (2020–2021)Ke‐Da Yu · Fudan University2 papers (2020–2023)Zhimin Shao · Fudan University1 papers (2020–2020)Ming Jiang · Xinjiang Medical University1 papers (2023–2023)Wei Pan · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2012–2012)Yin Liu · Wake Forest University1 papers (2021–2021)Shuang Hao · Sun Yat-sen University1 papers (2021–2021) · 1 papers (2023–2023)Rui Ling · Jiangsu University1 papers (2023–2023)Yanming Sun · Harbin Medical University1 papers (2012–2012)Xinyong Sun · Harbin Medical University1 papers (2017–2017)Zhi-Min Shao · Fudan University1 papers (2021–2021)Jia Li · Hebei Medical University1 papers (2017–2017)Xiaohua Zeng · Chongqing University1 papers (2023–2023)